Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 223

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Arie Apel, MD, Yishay Ofran, MD, Avraham Frisch, MD, Yakir Moshe, MD, Ofir Wolach, MD, Chiya Leibovitch, MD, Natalia Kreiniz, MD, Maya Koren-Michowitz, MD

Blood (2019) 134 (Supplement_1): 3902.

https://doi.org/10.1182/blood-2019-125720

Published: 2019

Journal Articles

Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy

Ruben A. Gößmann, Lei Wang, MD, Ming Ni, Mingya Yang, MD, Thomas Luft, Ute Hegenbart, MD, Stefan O. Schönland, MD, Patrick Wuchter, MD, Volker Eckstein, William Hermann Krüger, MD PhD, Ronit Yerushalmi, MD, Katia Beider, Arnon Nagler, MD MSc, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD, Anita Schmitt, MD

Blood (2019) 134 (Supplement_1): 3287.

https://doi.org/10.1182/blood-2019-125049

Published: 2019

Journal Articles

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Blood (2019) 134 (Supplement_1): 982.

https://doi.org/10.1182/blood-2019-129618

Published: 2019

Journal Articles

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

Shoshana Revel-Vilk, MD, Tama Dinur, PhD, Majdolen Istaiti, Dafna Frydman, DMV, Michal Becker-Cohen, MSc, Ari Zimran, MD

Blood (2019) 134 (Supplement_1): 4712.

https://doi.org/10.1182/blood-2019-123000

Published: 2019

Journal Articles

B Cell Specific Knockdown of the Erythropoietin (EPO) Receptor Attenuates EPO-Induced Bone Loss in Mice

Albert Kolomansky, MD, Naamit Deshet-Unger, PhD, Nathalie Ben-Califa, PhD, Zamzam Awida, Maria Ibrahim, B.Sc., Tamar Liron, PhD, Sahar Hiram-Bab, PhD, Howard S. Oster, MD PhD, Moshe Mittelman, MD, Martina Rauner, PhD, Ben Wielockx, PhD, Yankel Gabet, DMD, PhD, Drorit Neumann, PhD

Blood (2019) 134 (Supplement_1): 939.

https://doi.org/10.1182/blood-2019-127092

Published: 2019

Journal Articles

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Odelia Amit, MD, Yael Bar-On, MD, Irit Avivi, Tsila Zuckerman, MD, Galit Perets, MD, Israel Henig, MD, Itai Levi, MD, Dana Yehudai-Ofir, MD, Shimrit Ringelstein Harlev, MD, Ron Ram, MD

Blood (2019) 134 (Supplement_1): 5654.

https://doi.org/10.1182/blood-2019-128248

Published: 2019

Journal Articles

Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study

Xavier Leleu, MD PhD, Jo Caers, MD PhD, Barbara Gamberi, MD, Maaike Söhne, MD, Sonja Heibl, MD, Florence Suzan, MD, Abeera Mohammad, Sally Wetten, Evangelos Terpos, MD

Blood (2019) 134 (Supplement_1): 5578.

https://doi.org/10.1182/blood-2019-122938

Published: 2019

Journal Articles

COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting

Stefania Bettelli, Raffaella Marcheselli, Samantha Pozzi, MD, Luigi Marcheselli, Robel Papotti, Elisa Forti, M. Christina Christina Cox, MD PhD, Arianna Di Napoli, Tamar Tadmor, MD, Antonino Maiorana, Valentina Donati, MD, Sara Galimberti, MD PhD, Stefano Sacchi, MD

Blood (2019) 134 (Supplement_1): 1617.

https://doi.org/10.1182/blood-2019-125689

Published: 2019

Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA

Blood (2019) 134 (Supplement_1): 1845.

https://doi.org/10.1182/blood-2019-126606

Published: 2019

Journal Articles

Patient Reported Outcomes (PROs) Show Superior Quality of Life (QOL) of Patients with Chronic Myeloid Leukemia (CML) Treated with First Compared to Newer Generations of Tyrosine Kinase Inhibitors (TKIs)

Adi Shacham, MD, Lena Rosenman, Avi Leader, MD, Giora Sharf, Pia Raanani, MD, Uri Rozovski, MD

Blood (2019) 134 (Supplement_1): 4781.

https://doi.org/10.1182/blood-2019-129806

Published: 2019

Journal Articles

Preoperative Anemia and Blood Transfusion Requirement during Hip Surgery: Synthetic and Real Patient Cohort Data

Tsofia Inbar, MD, Eldad J Dann, MD

Blood (2019) 134 (Supplement_1): 3693.

https://doi.org/10.1182/blood-2019-125252

Published: 2019

Journal Articles

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Cédric Rossi, MD PhD, Marc André, Clémentine Joubert, PhD, Catherine Fortpied, Pauline Brice, Bénédicte Deau-Fisher, MD, Herve Ghesquieres, MD PhD, Luc Mathieu Fornecker, MD PhD, Anne-Claire Gac, MD, Julien Lazarovici, Aspasia Stamatoullas, MD, John Raemakers, Massimo Federico, MD, Marie Maerevoet, MD, Sarah Bailly, MD, Salim Kanoun, MD, Michel Meignan, Anne Ségolène Cottereau, Rene-Olivier Casasnovas, MD

Blood (2019) 134 (Supplement_1): 128.

https://doi.org/10.1182/blood-2019-125976

Published: 2019

Journal Articles

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Blood (2018) 132 (Supplement 1): 4452.

https://doi.org/10.1182/blood-2018-99-115971

Published: 2018

Journal Articles

Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms

Tiziano Barbui, MD, Arianna Ghirardi, PhD, Arianna Masciulli, PhD, Alessandra Carobbio, MSc, Francesca Palandri, PhD MD, Nicola Vianelli, MD, Valerio De Stefano, MD, Silvia Betti, MD, Ambra Di Veroli, MD, Alessandra Iurlo, Daniele Cattaneo, MD, Federica Delaini, MSc, Massimiliano Bonifacio, MD, Luigi Scaffidi, MD, Andrea Patriarca, MD, Elisa Rumi, MD, Clemency Stephenson, MD, Paola Guglielmelli, MD PhD, Elena Maria Elli, MD, Palova Miroslava, MD, Laura Bertolotti, MSc, Daniel Erez, MD, Montse Gomez, MD, Kai Wille, MD, Manuel Pérez-Encinas, MD, Francesca Lunghi, Anna Angola Figueras, MD, Maria Laura Fox, MD, Eloise Beggiato, MD, Giulia Benevolo, MD, Giuseppe Carli, MD, Rossella Rosari Cacciola, Mary Frances McMullin, MD, Alessia Tieghi, MD, Valle Recanses Flores, MD, Monia Marchetti, Martin Griesshammer, MD PhD, Alberto Alvarez-Larran, MD, Alessandro M. Vannucchi, MD, Guido Finazzi, MD

Blood (2018) 132 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2018-99-112387

Published: 2018

Journal Articles

Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study

Blood (2018) 132 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2018-99-112874

Published: 2018

Journal Articles

Efficacy of Adjuvant Low Dose Rituximab and Plasma Exchange for Acquired TTP with Severe ADAMTS13 Deficiency — Results of the ART Study

J. Evan Sadler, MD PhD, Joshua Muia, PhD, Leili Dolatshahi, MD, Lisa A. Westfield, MA, Patricia Nieters, RN, BSN, Anita Rodrigues, BA, Ana G. Antun, MD, Ara Metjian, MD, Jeffrey I. Zwicker, MD

Blood (2018) 132 (Supplement 1): 374.

https://doi.org/10.1182/blood-2018-99-113677

Published: 2018

Journal Articles

Adding Midostaurin to Intensive Chemotherapy in FLT3-Positive AML Patients. Results from a Multicenter Historical-Controlled Study

Tamar Berger, MD, Yakir Moshe, MD, Shilo Yaari, Ilana Hellmann, MD, Adina Aviram, PhD, Pia Raanani, Ron Ram, MD, Yishai Ofran, MD, Ofir Wolach, MD

Blood (2018) 132 (Supplement 1): 4005.

https://doi.org/10.1182/blood-2018-99-114154

Published: 2018

Journal Articles

Safety and Efficacy of Blinatumomab- Real World Data

Arie Apel, MD, Yishai Ofran, MD, Ron Ram, MD, Itai Levi, MD, Miri Zektser, MD, Maya Koren-Michowitz, MD

Blood (2018) 132 (Supplement 1): 5209.

https://doi.org/10.1182/blood-2018-99-116183

Published: 2018

Journal Articles

Direct Oral Anticoagulants and Mortality in Atrial Fibrillation

Martin Ellis, MD, Sergienko Ruslan, Hammerman Ariel, Sari Greenberg-Dotan, Erez Battat, Orly Hamburger-Avnery, MD, Dan Greenberg, Arbel Ronen

Blood (2018) 132 (Supplement 1): 5061.

https://doi.org/10.1182/blood-2018-99-111182

Published: 2018

Journal Articles

Tissue Molecular Genotyping Improves Patient Blood Management in Syrian Injured Patients Treated in Israel

Luiza Akria, MD, Masad Barhoum, Simona Zisman-Rozen, Celia Suriu, Andrei Braester, MD, Ety Shaoul

Blood (2018) 132 (Supplement 1): 5076.

https://doi.org/10.1182/blood-2018-99-114061

Published: 2018

NARROW

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

B Cell Specific Knockdown of the Erythropoietin (EPO) Receptor Attenuates EPO-Induced Bone Loss in Mice

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study

COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Patient Reported Outcomes (PROs) Show Superior Quality of Life (QOL) of Patients with Chronic Myeloid Leukemia (CML) Treated with First Compared to Newer Generations of Tyrosine Kinase Inhibitors (TKIs)

Preoperative Anemia and Blood Transfusion Requirement during Hip Surgery: Synthetic and Real Patient Cohort Data

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms

Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study

Efficacy of Adjuvant Low Dose Rituximab and Plasma Exchange for Acquired TTP with Severe ADAMTS13 Deficiency — Results of the ART Study

Adding Midostaurin to Intensive Chemotherapy in FLT3-Positive AML Patients. Results from a Multicenter Historical-Controlled Study

Safety and Efficacy of Blinatumomab- Real World Data

Direct Oral Anticoagulants and Mortality in Atrial Fibrillation

Tissue Molecular Genotyping Improves Patient Blood Management in Syrian Injured Patients Treated in Israel

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only